Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Simple look under RGBP at Yahoo finance page gives all the PRs minutes after release or my mobile app from stock broker will list official PRs minutes after release as well. Other things, like listings at conferences before the PRs release, is stealth research by N4T and fellow watchers.
And Snooty, another PR stated that 2 of those abstract presentations have been upgraded to oral presentations - significant development.
Another interesting admittance from the PR you cited is this:
Ditto. Those hoping C. Ichim exists the conference waving a contract like a sporting draft are not living within the means of the real world here. But the conference presentations defintitely will amount to something because these are international events with the latest science and C. Ichim presentations are not on HemaX (old news already in medical journal), but on new developments of the past several weeks.
The potential effects of investor and pharmaceutical interest is much higher than a PR.
Many factors and multipliers to factor in. Just know that I have followed other companies with INDs in phase trials that run between $1 and $3, but haven't examined all the share counts etc.
Just having an IND approved, does not mean you have a cure. Most phase trials do not end up with approved drugs.
But this is where Cell treatments do not have the track record of drugs, but have great potential in reducing side effects. As I say, many factors, including who owns the IP and that is where Koos' history, like it or not, is going to affect us to the downside. And from some who have posted here in the past, not the best guy to deal with on behalf of shareholders interest. Hopefully some success will soften him up and expand his vision.
That question is above my pay grade.
But at this point, I'd dare to say and hope that with the IP increase with the acquisition of existing Ichim patents and the new ones filed along with the potential and progress of C. Ichim research on NR2F6 and NR2F2 attacking the stem cells and not the tumor, all in RGBP pipeline, any IND approval should push us over dollar mark with existing O/S count.
If more than one IND gets even human trial approval, I think price then doubles on second IND, but this is all guesswork.
So much depends on numbers of targeted patients, whether or not new competing treatments are approved or in development....
It's a race and I'm not a biotech science expert, but my gut feeling is that if there are no major obstacles in C. Ichim's way and things develop, then a major financial deal is possible (not saying probable), but possible even within 2015 since we assume the patents filed have locked in the various potential gene silencing combos that target either NR2F6 or NR2F2 and so others would have to pay licensing fees to develop their own combos.
HemaX, because it receives auto Orphan Drug status, should easily push us over $1.00 if FDA approval is received within the next 6 months. After that, with conversion note shares flooding into the scene, it gets harder.
Will do.
Typically, lab results and pipeline promises don't spur partnerships, I agree, but that has proven otherwise by billion dollar deals in this sector already this year.
This won't go straight up everyday, but we are past the "typical" trends of 2014 in all areas: employees, funding, science, IP and communications.
Well, so much for guarantees.
Yes, but research doesn't turn directly into dollars in PPS unless some type of collaborative venture is undertaken which pumps money directly into RGBP for use of IP.
C. Ichim's "revelation" might just be a scientific insight or "in vitro" validation that will need time to develop. I'm with you in the possible significance of the moment, in especially in light of the venue of the AACR meeting, but unless there is a contract (doubt it immediately) or investors convinced its time to buy into RGBP, we don't want to predict a PPS rocket launch by end of April.
More likely is a more steady stepping up in PPS week to week as the science and INDs move forward.
I'm okay with progress over the year and price getting to 1.00 by Sep, but I'll certainly rejoice if it gets there before that, because any climb before Sep is not subject to all the convertible note shares being released into the climb.
There's more support on the L2 than is showing.
ATDF showing 5,000 support at .32, just absorbed over 13,000 share sells and hasn't changed.
Good luck to those who try to DT this for a .02-.05 spread, especially in light of the AACR coming up in less than 10 days and Cold Spring Harbor conference currently in session.
After all, there are certainly people that will find out what the news is that C. Ichim will share at the conference before the conference, and they may also have interested friends.
Guaranteed? What will you pay on the dollar if the "guarantee" doesn't take place?
Based on what objective facts of DD is this based?
Please provide links to ENTB abstracts or presentations at the following in years past:
Cold Spring Harbor
AACR
I really do want to follow up on your insights.
Agreed, and once the larger investment community takes notice, anything this side of .50 will be bottom bargain prices. When deep pockets begin entering, everyone here will be very aware that something very different is taking place.
I say we go quickly to .80-1.00 intraday when the first larger investment company takes a bite.
Think about it PPCH at .03 has already exchanged over $238,000 worth of shares which would be well over 600,000 shares of RGBP at current pricing, but we are only at 160,000 shares traded.
What would 5x the current volume of shares being traded do the price? We, we wouldn't be bickering over .25 or .30/pps. Someone decides to put $100,000 into RGBP, they would need to buy over 285,000 shares alone and big investment people don't wait for the price to come back down a penny to do it. It's a steady programmed tick of buying throughout the day until the shares are purchased. I haven't seen that yet in RGBP, but the day is coming and you will know when it happens.
And if they can do that, cause the cancer stem cells to mature using their "cell differentiation" process, then they can change the cancer stem cells into mature non cancerous cells and the tumor stops growing. It stops the cancer and then other treatments can allow the immune system to shrink the tumor itself. End of cancer.
Yes, this is BIG news. This isn't news of a drug showing "great potential" in allowing cancer patients to survive another 6 months with heavy doses of drugs. This is news of a treatment that causes the cancer to disappear and the patient to return to their previous state of health!
Well, this is a PR I like for several reasons.
1. We knew it was coming since someone on this board discovered the AACR abstract last week. (Great job and I'm sorry I forget who first shared that info!)
2. PR builds on C. Ichim's current abstract at Cold Spring Harbor and comes on the heels of the announcement of the upgrade to oral presentations at another international conference. Great momentum builder to have these piggy backing across the nation.
3. The PR seems to give us more information that not only has the NR2F6 target been identified, but that there is some bigger news about this that will be released at the AACR conference that has not yet been released. That's the biggest nugget I see in this PR. So C.Ichim's presence at the AACR will not be to rehash papers already written, but to announce some new discoveries and advancement - wonderful opportunity with the sector so hot and gaining so much coverage these days.
While I don't think they exit any of these conferences with a signed contract and money in their pockets from big pharma, all these will serve to put RGBP on more screens of pharma and investors alike.
Big money from investors has not yet entered this game. PPCH is a perfect example when bigger pockets enter a small company. Check their chart and volume over the past month. It's a penny with daily trades that cover hundreds of thousands of dollars and has gone from sub-penny to 3 cents on sustained interest. Once RGBP gets that kind of interest, you'll see a hundred thousand shares traded every 30 min throughout the day. We aren't there yet, but we are getting much closer.
Only Koos can get in the way and destroy the party. Let's hope he stands back and lets the others carry this company forward for the benefit of all shareholders.
CT and Laddyman, also remember that RGBP is in penny land and not on the daily radar of large investors for PRs. Often, smaller company PRs have a delayed effect as larger investment companies decide whether or not to jump in.
For me, today's action and volume is too low for that to be the case. If a large investment company decides to take a bite, you will see a steady purchase of tens of thousands of shares every minute and this will walk almost straight up as we have experienced a bit in the past or you can see in charts like PPCH, MVIS...
GLTA
My complaint there is that shareholders gain no value, but Koos and Angel investors gain almost instantly a 800% share value gain on their notes. But you are right, all things being equal, the dilution of OS should have pushed PPS even lower.
Ha ha ha is right. C. Ichim was assigned to develop cancer vaccine for animals just last year at ENTB, long after its PPS had been destroyed. Come on, who is bluffing here?
Wynston, what do you think the price would be without news? My guess is much lower. We could be back at .10 if the pattern of one PR and then 2 months of silence were the norm, only to be broken by the 10-Qs and 8-Ks.
The pattern of regular updates and the PRs on IP and conferences are a quick and easy way for new investors to get a grasp of the company's activities and scope. While not an immediate and long term pressure on the PPS, these PRs will eventually lay the ground work of a normal company profile which should pay off in future PPS pressure to the upside.
Yes, the question will be how will Koos structure the agreements?
By arranging for himself and the employees to get special shares and incentives or something that will bring value to the whole company so as to include shareholders as well.
The science is there. The jury is still out on what shenanigans Koos might engage in.
CT, I think you may very well be right and that is why the structure of the "Angel" notes and "incentive" shares begin their release at 6 months over the course of the following 6 months.
In other words, as soon as RGBP is able to announce the FDA Green light for HemaX human trials, Koos and Co can begin dumping shares into the spikes of buying and then as good news is released 1, 3 and 6 months into the human trials.
They have set themselves up very nicely for BIG MONETARY success as all their shares are purchased at .028/share. That means even at .50/share $50,000 note just became $892,857 and if they sell in pieces from .50 to 1.00 you see the picture.
So C. Ichim and Regen have lined up for April-May
Cold Spring Harbor Conference begins tomorrow with abstract on DiffronC, April 8-11th, NY
AACR (American Association for Cancer Research) 2 abstracts, 1 by T. Ichim and one by C. Ichim on April 22nd in Philadelphia Not yet announced in RGBP PR, but officially posted to AACR conference websiteLink to index
13th International Symposium on Myelodysplastic Syndromes, 2 orals and 1 abstract covering HemaX and DiffronC, April 30th- May 1, NY
2015 is the year of growing up for Regen and the more Regen is associated with science and scientists like the Ichims and Wei-Ping Min and less identified with Koos, the further we may go. Just hope Koos doesn't want it all for himself and will let the company and shareholders benefit as well like a real company. Hoping for the best. It's already a better year than 2014 as far as real advancement of growth I think. Holding my breath that before end of April we will also get some kind of news that tells us that GLP safety testing for HemaX is progressing.
Highlighting a section from the N4T link that focuses on the same target as dCellVax I believe as well as stating that the future is combination therapies. This is good news for us as the more IP Regen builds, the greater the chances for co-development with a major player wanting to use one of the targets RGBP is developing in combination with their own research. Very good news.
And I see that as a potential plus. File for US and worldwide rights. If you have to wait for FDA in USA, but can partner with someone like Benitec in a foreign country (after all, we are licensing from them), then maybe Benitec will partner with RGBP to carry the treatment to trials in Australia. Bonus if it would happen.
Sure thing is that if C. Ichim keeps adding IP, patents and exposure through major national conference presentations, we will be much further ahead than we would be otherwise.
Happy Easter CT and others on board.
Nice way to begin a new week.
Hard to know whether or not we get significant news tomorrow, but I like the fact that we get a PR on a different day, but still within a frequent schedule.
My gut guess is the next PR might be Thursday/Friday as an update to the conference presentation of C.Ichim this week.
The building up of IP is a good thing and seems that they are very focused on getting the most effective, potent and probable combination for success before filing a new IND on NR2F6 that might be a combo treatment targeting both NR2F6 and NR2F2.
Looks like you just found next week's PR topic. April 8th at the CSHC and a couple weeks later at the AACR. Good stuff. She's earning her investment shares while continuing the research. NR2F6 to me could be our golden egg of the future.
Another quiet day for RGBP. With markets closed tomorrow, we are only one day away from the next potential PR. (At some point they won't come every week.)
Might see more market action in RGBP Monday-Tuesday ahead of the conference, but expect low volume until something else major happens which I think is most likely weeks away. Crossing my fingers that HemaX safety tests are already underway somewhere.
I agree it can't hurt. Well, nice to see that no one is interested in selling today and yesterday, so the post divvy sell off may have run its course and we can build off new base with new people coming along and pushing this higher next week with Ichim's presentation at the cancer conference.
6 months to get this to a dollar before the convertible notes are released, that's my new hope and goal. Anything beyond is pure joyful bliss.
Don't want to get anyone's hope up too high (including myself), but next week might be a positive one if we get a good PR on Tuesday regarding safety tests underway or positive update on dCellVax right before Dr. Ichim's display is seen at the cancer conference from Wed-Friday.
Hope Cavens will be walking the floor there highlighting Ichims charts and shaking hands.
Makeitto, you should send this on and make sure Todd Cavens is aware and is not just counting his recent shares.
Look guys, the avg number of shares trading in RGBP according to Yahoo Finance is 95,659 shares or 20-25K/day. I have more shares than that and I'm a nobody in the financial world, so don't get caught up in the minute to minute world of this stock.
If you believe we will have 2 INDs approved by end of 2015 and have money to spend, then any and every dip is an opportunity to pick up shares and any blip up on 20,000 shares may be a short term gain.
When the company has progressed enough to bring in money, it will be obvious to all even without a PR as this will trade in the hundreds of thousands of shares. Until then, we wait for our weekly PRs.
I'll be waiting and watching and hoping it plays out well for us, but Koos did not do the shareholders a favor in how he handed out shares to "Angel" investors for .028/share and raised $500,000 when he could have raised millions for the same amount of shares given out.
That's what should make every shareholder mad. Good business deals are deals that are good for the business. Paying himself back a $57,000 loan with shares at a 65% discount that a few days later are worth over $400,000 I would not call a fair business transaction, but shady and possibly an action that could be prosecuted if an issue was made of it.
But as I've posted and analyzed in the past, my hope and trust is in the Ichims, not Koos and if the $500,000 is not in the bank in this quarters financials, then the shareholders may need to seek accountability, that's all. Yes, I still hope that the safety trials for HemaX and dCellVax don't get hung up for a couple months more delays. If we get HemaX approved by July and dCellVax by Sept we should be able to weather the initial unloading of these shares, but everyone must realize that if you purchased something at .03 and it goes to .50, how many shares would you hold after such a value increase with Koos at the wheel?
Consolation for me will be if HemaX, dCellVax and or a treatment of NR2F6 has been green lighted for human trials before Sep and the price has gone over $1 so I can exit before Koos and Co cashes in their millions of shares.
Ok, we need some new speculation in light of today's interesting PR. Interesting because it's a bit unusual for a company to issue a PR that is a summary/clarification of the previous week or so releases.
Here's the bad news:
1. All convertible notes were changed into common shares at a 65% discount to the lowest closing bid price over the previous 30 days, which for most shares is probably 65% off .08 or .028/share meaning $50,000 became 1,785,714 shares which at .20 is now worth $357,143. This stinks. It's not uncommon I believe to raise funds through a straight discounted sale of shares at 20-30% below market, like the company could have done for .12/shares after it went to .30-.44 and raised 6 million dollars, but the way Koos has done this, the stock price doesn't have to go anywhere for the next 6 months in order for these "Angel" investors to make hundreds of thousands off of $50,000.
2. Koos' $2,000 debt payment in convertible notes just became a payment of $14,286 at PPS of .20 and a payment of $7,143 at .10 and a payment of $2,000 in debt of $3,571 at .05/share. I challenge anyone to show how this is done in the sense of good business strategy! This is Koos setting himself and acquaintances up nicely for profit even if they sell all their shares at .08 because at .08/share they are guaranteed 65% profit and everything above goes up exponentially.
Today's PR, I'm sorry, is a sham trying to put "good business planning and necessary financial means" over the facts of the documents that cry out SHAM and no concern for shareholders outside of those in the 8K, because the 8Ks just put a tremendous amount of downside pressure from 6 months on.
Even if of the 59M shares issued/converted in the past month, only half are released at a rate of 1/6th per month, that still roughly 5million shares per month or at our current trading avg of 98,000/day, that 51 times the daily avg released every month for 6 months which potentially will be a 6-12 month wall crashing down upon us unless BIG BIG news comes before then.
Basically, my friends, Koos has given us a 6 month lease on our shares before he and others cash in big and potentially send the price of the stock capitulating unless strong gale wind forces are behind us.
My hope has taken a big hit today in reflecting on how Koos has set this up, basically no different than in years past, except this time he paid himself in shares at a 65% discount when the stock had hit its lowest level and then started the PR campaign immediately after to raise the price, which is why everyone immediately converted their notes into shares even though they can't sell them for 6 months. I had so hoped he had changed and was really setting the company, not himself and friends, for success. But people changing for the better is hard to come by. I guess, aside a miracle of sorts, I have to realize that I invested a big part of my future in a self serving CEO.
The only good point here is, none of the "Angel" (cough) investors, foresee the price going back below .08 in the next 6-12 months or they wouldn't have cashed in their chips so early. [Maybe we can pray that that is because they think it will be significantly higher 6 months from now.]
You know, if we don't see FDA approval of both HemaXellerate I and dCellVax in the next 6 months, Koos and Kronies will be an applicable title and I myself, might contact my relative at the SEC investigating pump and dump scenarios.
Koos doesn't care about shareholder value. I can only hope the Ichims, with their science, can create the value we need to move this higher in spite of Koos' antics.
It definitely will in fundamentals, but with 3 billion shares O/S and plenty of people wanting to exit, I am not confident that BMSN can hold a share price value increase as well as RGBP should be able to.
I exited while BMSN was in teens (at great loss) to buy RGBP shares will proceeds. Both are down, but BMSN is further down in price than RGBP.
For those entering BMSN with fresh money now, it might still be a very good play for spikes and such, but if all its value has to come from RGBP, then investors and traders will be focused on RGBP in my opinion and BMSN price will lag at least in time. I do not see BMSN rising in sync on a daily basis with RGBP value.
AIMO
Good question. BMSN owns majority stake in RGBP with Koos owning BMSN. So, if Koos would so choose, he could allow for a buyout of RGBP and score twice, first with value of buyout of RGBP shares and then with BMSN value going up because of purchase of RGBP.
But for now, I think the spinoff of RGBP was to concentrate the IP into a company with lower O/S float, which is why the multiplication of shares at .01 each to pay off small debts is foolhardy and ridiculous from any business perspective other than Koos and friends personal gain by getting shares at .01/dollar.
I have sold all my BMSN shares as I don't think the value of BMSN will keep up with RGBP should RGBP succeed, but if RGBP rockets and BMSN lags, one can always sell some RGBP and pick up BMSN hoping it will follow.
AIMO
I don't have an issue with incentive shares Dmort, I do have an issue with paying off $2,000 in debt with company stock instead of cash as it merely dilutes the company and value at a time when the company already has little value in PPS.
My scenario 4 envisioned a sale of 50,000,000 shares of RGBP to investors that would raise $6,000,0000 or more at a minimum price of only .12/share or higher. That would have given the company years of cash and ability without question to pay for GLP, R&D as well as human trials.
Where are we today. It appears 50,000,000+ shares of common stock have been issued for a cash return we are told of only $500,000 - $700,000. How is that a good business decision for the future of the company? At this rate we would have to project O/S to eventually rise to 500,000,000 or the billions that plagued BMSN if Koos continues to sell shares at a penny each. Instead of $5 million in the bank, we have $500,000 since Koos values the company at only a penny a share to raise funds.
GM, you think Koos was made aware of our comments on the board? Almost seems to be a response in kind of my lamentation last night about his issuing of stocks and wondering whether there is money in the bank or not.
New4This, don't understand the posting of the link other than it showing that there is a lot of competition in the arena.